Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-40 40L CD-154 TBAM Gp-39 FCGR2-A HIGMX1 Anti-body antiCD40L
- Product Overview:
CD40 ligand (CD40L) is a type II transmembrane protein and member of the TNF superfamily encoded by CD40LG in humans.{57013} It is expressed primarily by activated T cells, as well as activated B cells and platelets and, under inflammatory conditions, can be induced in natural killer (NK) cells, mast cells, basophils, and monocytes. CD40L trimerizes to engage its receptor, CD40, on various cells, including B cells, dendritic cells, monocytes, platelets, macrophages, endothelial cells, and myoblasts, to induce cell type-specific signaling and activities. Soluble CD40L (sCD40L) is produced by proteolytic cleavage of CD40L at the cell surface and is found in the circulation.{57014,57017} sCD40L retains its ability to trimerize and bind to CD40, indicating CD40L can act as a cytokine.{57014} CD40L stimulates the proliferation of, and increases IgE secretion in, isolated human tonsil B cells.{65438} Immune complexes targeting CD40L induce thrombocytopenia and thrombosis in transgenic mice expressing the gene encoding the human IgG receptor (FCGR2A).{65439} Mutations in CD40LG are associated with X-linked immunodeficiency with hyper-IgM (HIGMX-1), a disorder characterized by an immunoglobulin isotype switch defect, increased serum IgM levels, ineffective T cell-B cell cooperation, and recurrent bacterial infections.{65440} Cayman’s CD40 Ligand Chimeric Monoclonal Antibody (Clone hu5c8) was produced recombinantly from the original hu5c8 antibody sequence and can be used for flow cytometry (FC) and Western blot (WB) applications. The hu5c8 antibody was generated by fusing human IgG1? constant domains to the antigen-binding domain of a mouse anti-CD40L monoclonal antibody.{66201}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.